HCPLive Network

National Epilepsy Awareness Month

November is National Epilepsy Awareness Month (NEAM), which was established to “highlight the growing need for awareness about epilepsy” as a way to help “dispel myths about epilepsy, teach proper seizure first aid and improve the quality of life for all individuals, families, and friends with epilepsy.” Epilepsy.com Editor-in-Chief Robert Fisher, MD, PhD, wrote in the November newsletter that epilepsy “remains the most prevalent serious disorder that is able to affect people across the full spectrum of ages.”

People who have seizures not only experience pre- and post-seizure symptoms, they become afraid and embarrassed should they have a seizure in public. In a November 2000 issue of Epilepsy & Behavior, more than 1,000 epilepsy patients were asked what the worst thing is about having epilepsy, and the number-one answer was fear—fear of dying, losing their job, or having a seizure while driving—followed by humiliation. It doesn’t help that many neurologists will not prescribe generic versions of the more than 20 AEDs (if they’ve received FDA approval), because there may be a risk that their patients could have a “breakthrough” seizure due to “the disparity between how AEDs work and the FDA requirements for generic equivalents”; the FDA “allows for significant differences between [brand-name] and generic drugs.” This is where the cost of medication comes into play, as there are many patients who cannot afford the high cost of brand-name drugs.

The above are just some of the reasons why the results from a CDC study released in August requires attention, covered in a previous MDNGLive article.

Because there are so many epilepsy patients who are under-treated, programs like NEAM and The Epilepsy Phenome/Genome Project are essential.

“Misconceptions about epilepsy are widespread,” says Rosemarie Kobau, a behavioral scientist with the CDC’s Epilepsy Program, co-author of the study. “Until there’s better understanding—among physicians and the public alike—there’s unlikely to be much progress made.”


 


Related Article on HCPLive:

Black Box Warnings: 11 AEDs Are Evaluated


Additional Resource:

American Academy of Neurology Position Statement of the Coverage of Anticonvulsant Drugs for the Treatment of Epilepsy
 

 

 



Further Reading
Even though the active ingredient in marijuana can be associated with memory impairment, it may slow or halt Alzheimer’s disease.
For the second year running, physician turnover remains at the highest rate since 2005, according to a report published by the American Medical Group Association.
For physicians trying to balance various financial and time pressures, ethical dilemmas are common, according to an article published Aug. 7 in Medical Economics.
There is no link between vitamin D levels in infancy to adult-onset multiple sclerosis, according to research conducted by the Karolinska Institutet in Sweden.
An investigational drug that researchers hope will reverse nerve damage in patients with multiple sclerosis (MS) has been found to be safe and well tolerated in early trials. The big question is whether it will work, researchers said.
Treatment-naive patients with multiple myeloma frequently have sensory deficits, according to a study published online Aug. 25 in the Journal of Clinical Oncology.
Cerebrospinal fluid biomarkers for Alzheimer's disease, particularly β-amyloid 42 (Aβ42), are strongly associated with AD diagnosis, independent of APOE genotype, according to a study published online Aug. 27 in JAMA Psychiatry.
More Reading